PESTICIDE RESIDUES IN FOOD - 1980 Sponsored jointly by FAO and WHO EVALUATIONS 1980 Joint meeting of the FAO Panel of Experts on Pesticide Residues in Food and the Environment and the WHO Expert Group on Pesticide Residues Rome, 6-15 October 1980 IMAZALIL Explanation Imazalil was reviewed by the Joint Meeting in 1977 (FAO, 1978) and a temporary ADI for man was estimated to be 0-0.01 mg/kg body weight. Imazalil is a moderately toxic fungicide from the group of N-substituted imidazoles. Studies in rats have suggested that imazalil is rapidly absorbed, distributed, metabolized, and excreted following oral administration, with the major quantities of metabolites occurring in urine and faeces within 3 days of administration. Imazalil does not bioaccumulate. Tissue residues are observed predominantly in those parts of the body associated with biodegradation and elimination. Imazalil is not mutagenic as evidenced by a dominant lethal study in mice and is not teratogenic in rats. Long-term studies in the rat and a 2-year study in the dog were believed to be inadequate because of unresolved pathology questions concerning rat kidney and dog liver. Based on these considerations, a temporary ADI was allocated and further work was requested with respect to additional long-term, short-term, acute toxicity, pharmacokinetic and metabolic studies. Additional data (and a further interpretation of the previously reviewed data) were submitted, reviewed, and are considered in this monograph addendum. Further metabolic studies with imazalil labelled with 14C and further information on the nature and level of metabolites and degradation products in plants were considered desirable. A study was set up in order to provide information on the metabolic fate of imazalil on growing banana plants. The results of experiments have been submitted to the Joint Meeting for evaluation. Additional information was obtained on use pattern and national tolerances. DATA CONSIDERED FOR DERIVATION OF ACCEPTABLE DAILY INTAKE BIOCHEMICAL ASPECTS Absorption, distribution, and excretion A single lactating goat was orally administered imazalil (3H, tritium-labelled) twice a day at a daily dose of 1.0 mg/kg body weight for 3.5 days. Twenty-four hours after the final dose, the animal was sacrificed and tissue residues were determined. Qualitative and quantitative evaluations for tissue and excreted residues were made. Within 24 hours of the last dose, 96.6% of the administered imazalil was excreted, predominantly in the urine (70%). Approximately 0.14% of the administered radioactivity was secreted in milk. (A slight translocation of the tritium isotope to water may have made this milk residue higher than the actual imazalil residue). Tissue residues were extremely low, not exceeding 0.03 mg/kg. Over the course of the study, an attempt was made to determine whether translocation of the radioisotope tritium had occurred with water. It was observed that very little tritiated water was recovered, confirming the stability of the radioisotope in the metabolism study. Within 36-hours, a steady state appeared to be reached with respect to residues in milk and the plasma level of imazalil. The steady-state concentrations in all cases were extremely low. In urine, approximately 15% of the radioactivity was present as free base metabolites and 14% as conjugated basic metabolites. About 30% of the urinary metabolites were acidic, polar products. The metabolic sequence with respect to the goat was almost identical to that previously proposed for the rat. After the last dose, plasma radioactivity decreased rapidly with the half-life of approximately 19 hours. Highest tissue levels were measured in the GI tract and in tissues associated with biodegradation and excretion. It was concluded that imazalil is rapidly absorbed and eliminated from the body (within 24 hours). Approximately 70% of the residue was found in urine, 26% in the faeces, small fractions were observed in milk and as a residue in tissues (tissues predominantly related to the excretory system). The steady-state condition was rapidly reached on multiple dosing and residue data did not suggest bioaccumulation (Meuldermans et al, 1979). Biotransformation Studies on the metabolic fate of imazalil (predominantly in excreta) showed that imazalil was extensively metabolised with only about 3% of the total administered dose excreted as unchanged imazalil in the faeces. More than 10 acidic urinary metabolites were detected. Five major basic metabolites were characterised. Figure 1 demonstrates a qualitative evaluation of the metabolism of imazalil. Imazalil was metabolised extensively in the goat with only approximately 3% of the parent chemical recovered unchanged, predominantly in the faeces. Five major basic metabolites were characterised resulting from oxidation and degradation of the imidazole ring, from epoxidation and subsequent hydration of the molecule; and oxidative O-dealkylation (Meuldermans et al, 1979). The same qualitative metabolic picture with imazalil and its congeners has been seen in various mammalian species. In man and the rat, metabolism of a drug similar in chemical structure to imazalil (econazole) was reported to be similar. Additionally, the same pathway was observed in monkey and dog as well as rats with respect to other chemicals of this class of N-substituted imidazoles (Heykants, 1978). From all the data on imazalil and on the congeners of imazalil, it appears that the metabolic fate in all mammalian species is comparable.TOXICOLOGICAL STUDIES Special studies on reproduction Groups of rats (10 male and 20 female rats/group) were fed imazalil in the diet at dosage levels of 0, 50, 200 or 800 mg/kg and subjected to a standard 3-generation, 2-litter per generation, reproduction study. Observations included: growth, food consumption, mortality, and the standard indices of reproduction (mating, fertility, gestation, viability and lactation). The reproductive performance of rats was unaffected by imazalil at any dose level. There was no maternal mortality and the parental generations were unaffected by imazalil. No foetal abnormalities nor embryonic effects were noted. Litter size, weight and survival were normal. There were no effects on the reproductive performance of rats continuously fed imazalil in the diet at levels up to and including 800 mg/kg (Marsboom, 1978). Acute toxicity Rat Chemical Form Sex LD50 mg/kg (CL) Nitrate M 343 (262-448) F 288 (221-377) Sulphate M 355 (272-464) F 309 (237-404) Acetate M 371 (284-485) F 309 (237-404) Free Base M 343 (262-448) F 227 (174-297) All data were generated with adult rats, administered imazalil orally as an aqueous suspension. The acute signs of poisoning were the same for each chemical form of imazalil. These included: ataxia, piloerection, hypotonia, hypothermia, exophthalmia, tremors, salivation, lacrimation, diuresis, diarrhoea, palpable ptosis, and loss of the righting reflex (Niemegeers, 1979). Long-term studies Rat Groups of rats (50 male and 50 female Wistar rats/group) were administered imazalil in the diet at dosage levels of 0, 25, 100 or 400 mg/kg for 24 months. The animals were 3-4 months of age at the initiation of the carcinogenicity study. Animals were examined daily for behaviourial changes and toxicity. At the conclusion of the study, gross and microscopic examination was performed on all surviving animals. During the course of the study, examinations were performed on animals that had died or were sacrificed in extremis. Microscopic examinations were performed on the major tissues and organs and on all lesions that were noted during the course of gross examination. There was substantial mortality over the course of the study, and very few animals survived the full 24 months. It was considered that this was due to the fact that the animals were 3-4 months old at the start of the study and that they were not maintained under SPF-conditions. Evaluation of the data, relating to the time on study at which animals died, did not suggest that imazalil contributed to the increased mortality or the accelerated death rate. There were no dose-related events noted on gross pathology. There were no significant differences with respect to the overall tumour rate or the individual types of tumours reported in any of the does groups. There is no evidence that imazalil was responsible for tumour formation in any organ or tissue examined in the study (Marsboom and Herin, 1979a). Mice Groups of mice (50 male and 50 female albino, Swiss mice/group) were administered imazalil in the drinking water for 18 months at dosage levels of 0, 6.25, 25, or 100 mg/kg. It was approximated that the dietary levels reflect an intake of 0, 2.5, 10 or 40 mg/kg body weight based upon an assumption that each mouse drinks approximately 100 ml/week. All animals were examined daily for behaviour abnormalities and clinical toxicity. At the termination of the study, gross and microscopic examinations were performed on all surviving animals. A complete examination was performed on animals dying during the course of the study or that had to be sacrificed before termination. Gross and microscopic examinations were made on selected tissues and organs. (Gross examinations did not include organ-weight data). In addition, any tissue that was suspect of unusual lesion was examined histologically. There was no apparent dose-related effect on survival or on the time that mortality occurred. At the conclusion of 18 months, there was a substantial number of animals (greater than 25% in all cases) surviving. There were no significant differences with respect to survival in any of the test groups when compared to control values. There were no dose-related effects on health, behaviour, or appearance. An examination of the data on the occurrence of tumours in animals dying or sacrificed at the end of the study showed that there were no substantial differences between groups or with control values. Imazalil in the drinking water did not influence the occurrence of tumours. It was concluded that under the conditions of this assay, imazalil was not a tumourigen or a carcinogen in mice (Marsboom and Herin, 1979b). RESIDUES IN FOOD USE PATTERN Crop/ Formulation and mode Concentration disease of application ai Gherkin (outdoors) 20 EC, 0.025% 0.05 kg/ha powdery mildew Barley Pyrenophora spp. liquid, 2.4% 48 mg/kg seed Fusarium Wheat, barley seed dressing oats, rye 50 mg/kg RESIDUES RESULTING FROM SUPERVISED TRIALS The results of recent trials are summarised in Table 1. TABLE 1. Residues resulting from supervised trials in the Netherlands Crop Year of Application Residues in mg/kg, at intervals trial (days) after (last) application Number of Rate per Formulation treatments treatment kg ai/ha 3 4 ± 60 wheat 1976 1 0.125 liquid <0.011 wheat-straw 1976 1 0.125 200 g/l <0.11 gherkin 1977 1 0.1 liquid <0.011 (glasshouse) 200 g/l " 1977 1 0.15 200 g/l 0.04 (0.03-0.05) 1 Limit of determination FATE OF RESIDUES Eleven growing banana plants with a minimum of six leaves were used in the study. One of the banana plants (No. 1) was not treated and served for providing blank samples. The others were sprayed uniformly from above with a distilled water solution of 3N-imazalil-sulphate labelled specially on the asymmetric carbon. The plants were treated once, four, five or nine times consecutively at two-week intervals. The sampling of the individual plants was carried out as follows: One plant (No. 1) was sampled without any previous treatment, serving as a blank. Plants Nos. 2, 3 and 4 were sampled two hours (the time necessary for drying), four days and fourteen days respectively after a single treatment, Plant No. 5 fourteen days after the fourth treatment, plants Nos. 6, 7 and 8 two hours, four days and fourteen days respectively after the fifth treatment and plants Nos. 9, 10 and 11 two hours, four days and fourteen days respectively after the ninth treatment. Five different parts of the plants were investigated: mature leaves, new leaves emerged after the last treatment, psuedostem, rhizome and roots (petioles were considered part; of the psuedostem). The roots were out from the rhizome and the soil was washed off with water. The various parts of plants were minced and thereafter homogenised in water (1/5, w/v). The radioactivity levels of samples were measured in the aliquots of the homogenates immediately after homogenisation. The leaf homogenates of the treated plants and the spiked blank homogenate were subjected to repeated extraction. The radioactivity of the various extracts was measured. Some of the extracts were analysed with on-line radio HPLC after sample clean up on Sep-pak TMC18 cartridges. A part of leaf and a part of cigar leaf of plant No. 11 were prepared for autoradiography. The radioactivity levels in the various plant samples indicated fairly uniform sprayings and the absence of tritiated water or other volatile radioactive compounds. The leaves contained 95.2-100% of the total radioactivity recovered in the plants treated one to nine times. The radioactivity was practically all concentrated at the upper surface of the leaf tested with autoradiography. Transport of the radioactivity to the roots (0.32% maximally) or the rhizome (2.54% maximally) was minimal. In the leaves emerged after the last treatment less than 0.03% of the radioactivity recovered in the whole plant was detected. The metabolite pattern in the leaf homogenates was investigated after extraction. The scheme of extraction and the percentage ratio of the total radioactivity found in various extracts are shown in Figure 1. The differences between the various homogenates of the leaves of plants that were sprayed once, four, five or nine times were only minor. Attempts to extract the radioactivity from the final residues by soxhlet with chloroform, ethyl acetate and acetone or by batch extraction with 19% trichloroacetic acid failed. Analyses of various plant extracts on radio-HPLC revealed that the main part of radio-activity originated from imazalil and its metabolite alpha-(2,4-dichloro-phenyl)-1H-imidazole-1-ethanol (R14821). Unchanged imazalil constituted 33.8, 46.9, 37.1, and 22.3% and R 14821 23.4, 22.2, 27.9 and 37.8% of the radioactivity in the alkaline extracts of the leaves of plants Nos. 8, 9, 10 and 11 respectively. These results indicated that imazalil was degraded slowly as a function of time and that R 14821 was the main degradation product which was found in the pH11 extract too. Although the radioactivity in the extracts of pH 11, pH 9, ph 5 and pH 2 amounted to 15.38% of the alkaline extract, only a few small radioactivity peaks could be detected, which may be formed at least partly artificially from imazalil and R 14821 as similar peak patterns appeared on the chromatograms of the extracts of blank homogenate spiked with these compounds. The remaining part of the radioactivity might be explained with the presence of a large number of minor metabolites. R 14821 (45.4%) and imazalil (20.7%) were also major radioactive compounds in the soxhlet extract. The parent compound accounted for altogether about 20 and 15% of the total radioactivity while the proportion of R 14821 was 15% and 25% in the leaves of plants Nos. 8 and 11 respectively. A mixture of unidentified polar acid metabolites (7% of the total radioactivity) was found in both the pH 2 extract and the final aqueous layer. From 7-17% of the radioactivity in the leaf homogenates could not be extracted. The rest of the radioactivity, 35 to 45%, was due to a very large number of minor metabolites (Meuldermans, W. et al, undated). EVALUATION COMMENTS AND APPRAISAL Imazalil was reviewed by the 1977 Joint Meeting and a temporary ADI was estimated to be 0-0.01 mg/kg bw/day. Concern was expressed over the pathological changes observed in rat kidney and dog liver in two-year studies. On the basis of a re-evaluation by an independent pathologist the meeting concluded there was no difference between the control and the treated animals.
New data submitted to the meeting with respect to long-term carcinogenesis studies in two species was found to be inadequate to meet the current criteria for appropriate carcinogenicity studies. The survival rate of rats for 24 months was poor, and a carcinogenic evaluation could not be made with this species. In contrast to the rat study however there was a significant number of survivors in the mouse study. The metabolic profile of imazalil especially with respect to salt formulations appears to be well defined. Imazalil did not affect reproduction in rats. A temporary acceptable daily intake for man was reaffirmed on the basis of studies in rat and dog. In several respects the long-term studies reported to the meeting have been inadequate to evaluate fully the toxicological profile. The Meeting felt that while no immediate problems exist, a further adequately performed long-term study is required. Additionally, short-term mutagenicity tests should be performed. Additional information has now been provided on the metabolic fate of 3H-labelled imazalil on banana plants grown in a greenhouse, and on the results of supervised trials. The major part of the radioactivity (95.2-100%) recovered in the plants was present on the surface and in the upper layers of the leaves. Translocation of the radioactivity from the sprayed areas to the rest of the plant was minimal, since the rhizome, roots and new leaves that emerged after the last treatment showed very little or no radioactivity. The parent compound formed 15% of the total radioactivity recovered in the leaves of plants treated nine times, while the single major metabolite, alpha-(2,4-dichlorophenyl)-1H-imidazole-1-ethanol accounted for 25%. The rest of the radioactivity was due to a large number of unidentified minor metabolites, each representing at most only a few percent of the radioactivity. A considerable part of the unidentified material might consist of degradation products formed during the analytical procedure. The results of the metabolism studies and the supervised trials are in agreement with the findings discussed in the 1977 evaluation, and support the recommendations made then. Level causing no toxicological effect Rat: 5 mg/kg bw/day Dog: 1.24 mg/kg bw/day Estimate of temporary acceptable daily intake for man 0-0.01 mg/kg bw/day FURTHER WORK OR INFORMATION Required (by 1984) 1. An adequate long-term study on rats to define fully a no-effect level. 2. Short-term tests to evaluate the mutagenic potential. REFERENCES Heykants, J.J.P. On the metabolism of imazalil and related compounds in animals and man. A review. (1978) Unpublished summary review of published and unpublished metabolism data from Janssen Pharmaceutica submitted to the World Health Organization by Janssen Pharmaceutica. Marsboom, H. Oral three-generation study in Wistar rats. (1978) Unpublished report from Janssen Pharmaceutica submitted to the World Health Organization by Janssen Pharmaceutica. Marsboom, R. and Herin, V. Oral carcinogenicity study in Wistar rats. (1979a) Unpublished report (No. 667) from Janssen Pharmaceutica submitted to the World Health Organization by Janssen Pharmaceutica. Marsboom, R. and Herin, V. Oral carcinogenicity study in albino Swiss mice. (1979b) Unpublished report (No. 666) from Janssen Pharmaceutica, submitted to the World Organization by Janssen Pharmaceutica. Meuldermans, W., Swijsen, E., Hendricks, J., Wolstenborghs, R., Lauwers, W. and Heykants, J. (1979) Unpublished report from Janssen Pharmaceutica submitted to the World Health Organization by Janssen Pharmaceutica. Meuldermans, W. et al. The metabolic fate of imazalil on banana plants. Janssen Research Products Int. Service. R 23979/21. Niemegears, C.J.E. Comparative acute oral toxicity studies of the different salts of imazalil in rats. (1979) Unpublished report from Janssen Pharmaceutica, submitted to the World Health Organization by Janssen Pharmaceutica.
See Also: Toxicological Abbreviations Imazalil (ICSC) Imazalil (Pesticide residues in food: 1977 evaluations) Imazalil (Pesticide residues in food: 1984 evaluations) Imazalil (Pesticide residues in food: 1984 evaluations) Imazalil (Pesticide residues in food: 1985 evaluations Part II Toxicology) Imazalil (Pesticide residues in food: 1986 evaluations Part II Toxicology) Imazalil (Pesticide residues in food: 1991 evaluations Part II Toxicology) Imazalil (JMPR Evaluations 2000 Part II Toxicological) Imazalil (JMPR Evaluations 2001 Part II Toxicological) Imazalil (JMPR Evaluations 2005 Part II Toxicological)